18-METHOXYCORONARIDINE


Synonyms	(-)-18-methoxycoronaridine 18-methoxycoronaridine
Status
Molecule Category	UNKNOWN
UNII	KX8NQX91Z8


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	DTJQBBHYRQYDEG-JNBMDGLNSA-N
Smiles	COCC[C@H]1CC2CN3CCc4c([nH]c5ccccc45)[C@](C(=O)OC)(C2)[C@H]13
InChI	InChI=1S/C22H28N2O3/c1-26-10-8-15-11-14-12-22(21(25)27-2)19-17(7-9-24(13-14)20(15)22)16-5-3-4-6-18(16)23-19/h3-6,14-15,20,23H,7-13H2,1-2H3/t14?,15-,20-,22+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H28N2O3
Molecular Weight	368.48
AlogP	2.88
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	54.56
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	27.0

Assay Description	Organism	Bioactivity
Inhibition of Ach evoked currents at Nicotinic acetylcholine receptor alpha3-beta4 by 20 uM concentration	None	98.0 %
Binding affinity towards Nicotinic acetylcholine receptor alpha3-beta4 determined from kinetic measures of koff/kon	None	700.0 nM
Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 from guinea pig brain membranes	Cavia porcellus	20.0 %
Inhibition of [3H]naltrindole binding to Opioid receptor delta 1 in guinea pig brain membranes	Cavia porcellus	35.0 %
Inhibition of [3H]DAMGO binding to Opioid receptor mu 1 from guinea pig brain membranes	Cavia porcellus	50.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL607048
FDA SRS	KX8NQX91Z8
PubChem	15479177

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).